Generate Biomedicines Inc (GENB)

$16.00 +0.53 (3.43%)
Market Cap 1.98B
Revenue (ttm) 31.89M
Net Income (ttm) -203.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -782.38%
Debt to Equity Ratio 0.00
Volume 1,438,400
Avg Vol 419,730
Day's Range N/A - N/A
Shares Out 128.19M
Stochastic %K 78%
Beta N/A
Analysts Strong Sell
Price Target $25.00

Company Profile

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5...

Industry: Biotechnology
Sector: Healthcare
Phone: (888) 469-0055
Address:
101 South Street, Suite 900, Somerville, United States
MorganHoratio
MorganHoratio May. 16 at 1:01 AM
NVIDIA JUST UPDATED ITS PUBLIC STOCK PORTFOLIO HOLDINGS This is what Nvidia's stock portfolio looked like as of the end of Q1 Generate Biosciences $GENB - 833,325 shares Nokia $NOK - 166,389,351 shares Synopsys $SNPS - 4,821,717 shares Jensen Huang is building an unshakeable empire. Nvidia’s Q1 portfolio proves it's moving way beyond data centers. By holding 4.8M+ shares of $SNPS, Nvidia integrates CUDA into EDA software to control AI chip design at the source. Meanwhile, the massive 166M+ share bet on $NOK (over 8% of its book) is an aggressive play to dominate AI-RAN and turn global cell towers into edge-AI compute nodes. Nokia has quietly transformed from a legacy telecom into an AI infrastructure darling. Which Nvidia-backed proxy has more upside: Synopsys or Nokia? Let's discuss below!
0 · Reply
Johnnytwofour2
Johnnytwofour2 May. 15 at 11:20 PM
$GENB guys, its not the size that matters, its the connection that GENB and NVDA fell that counts. Serious face though, this is a big deal for a company like GENB. Being connected to the largest company in the world opens doors for them that others can only dream of. It might not be a material change this second, but the company is in a better position then they were at the close. They also happen to be trading lower then they were at the close. Seems like simple math to me. Good news + low price = $$$$, can confirm from personal experience that this math checks out sometimes.
0 · Reply
stockexchange01
stockexchange01 May. 15 at 10:35 PM
$GENB Yikes! Need to average down, is it worth it? So little volume.
0 · Reply
samfar
samfar May. 15 at 9:42 PM
$GENB only 117 watchers lol 1000 by Monday $NVDA bought 10M stake.
0 · Reply
Johnnytwofour2
Johnnytwofour2 May. 15 at 9:32 PM
$GENB I'll leave this here for the haters who want to hate, hate, hate, hate, hate. https://www.sec.gov/Archives/edgar/data/1045810/000104581026000042/xslForm13F_X02/information_table.xml
0 · Reply
EnronRetirementPlan
EnronRetirementPlan May. 15 at 9:21 PM
$GENB
0 · Reply
samfar
samfar May. 15 at 9:12 PM
$GENB anyone disputing that $NVDA did not purchase a stake in GENB is an idiot. Read the filing.
0 · Reply
Johnnytwofour2
Johnnytwofour2 May. 15 at 9:11 PM
$GENB This likely rips Monday again, profiteers need their beer money right now. Its been a red day overall in the market so makes sense.
0 · Reply
Olivia_Strickland
Olivia_Strickland May. 15 at 9:05 PM
$GENB down 5.19% AH off a 16 close, which is the polite version of "thanks for the +20% month, now give some back." mcap still 1.9B and the day ran 4.5x avg vol, so somebody got their fill and went home. quiet tape, no catalyst on my screen, just profit-takers tidying up before the weekend. anyone holding this through Monday or are we all flat into the bell? on my morning fade list: https://tapeboard.com/chart/GENB?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=genb-ah-dn-watch
0 · Reply
cloudhedge
cloudhedge May. 15 at 9:01 PM
$NVDA $COHR $CRWV $GENB $INTC NBIS NOK SNPS In its latest SEC Form 13F filing for the new quarter, Nvidia disclosed updated portfolio activity. The company initiated new positions in Coherent, a provider of optical and semiconductor technologies, and Generate Biomedicines, an AI-enabled biotechnology firm. It also increased its stake in cloud infrastructure provider CoreWeave to more than 47 million shares, further strengthening its exposure in the segment. For its existing holdings, Nvidia made no changes to positions in Intel, Nebius Group, Nokia, and Synopsys. Its Intel stake remains above 214 million shares, continuing to serve as a core holding while maintaining its broader exposure across telecommunications and AI hardware ecosystems. Follow me 👉 @cloudhedge for real-time updates and everything. Let’s make moves!
0 · Reply
Latest News on GENB
Generate Biomedicines price target raised to $22 from $20 at Morgan Stanley

2026-05-14T16:37:25.000Z - 1 day ago

Generate Biomedicines price target raised to $22 from $20 at Morgan Stanley

Generate Biomedicines price target raised to $25 from $16 at H.C. Wainwright

2026-05-08T10:32:33.000Z - 7 days ago

Generate Biomedicines price target raised to $25 from $16 at H.C. Wainwright

Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M

2026-05-07T11:16:37.000Z - 8 days ago

Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026, 6:16 AM EDT - 8 days ago

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines initiated with a Buy at H.C. Wainwright

2026-04-13T10:18:45.000Z - 4 weeks ago

Generate Biomedicines initiated with a Buy at H.C. Wainwright

Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald

2026-03-24T11:56:18.000Z - 7 weeks ago

Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald

Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald

2026-03-24T10:25:46.000Z - 7 weeks ago

Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald

Generate Biomedicines initiated with a Buy at Guggenheim

2026-03-24T09:15:42.000Z - 7 weeks ago

Generate Biomedicines initiated with a Buy at Guggenheim

Generate Biomedicines initiated with an Overweight at Morgan Stanley

2026-03-24T09:10:12.000Z - 7 weeks ago

Generate Biomedicines initiated with an Overweight at Morgan Stanley

Generate Biomedicines initiated with an Overweight at Piper Sandler

2026-03-24T09:00:31.000Z - 7 weeks ago

Generate Biomedicines initiated with an Overweight at Piper Sandler

Generate Biomedicines initiated with a Buy at Goldman Sachs

2026-03-24T08:35:11.000Z - 7 weeks ago

Generate Biomedicines initiated with a Buy at Goldman Sachs

Opening Day: Generate Biomedicines makes public debut

2026-03-02T16:30:40.000Z - 2 months ago

Opening Day: Generate Biomedicines makes public debut

AGMB BOBS EIKN FPS FVAV MANE OFRM

Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut

Feb 27, 2026, 12:57 PM EST - 2 months ago

Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut

Generate Biomedicines opens at $15.00, IPO priced at $16.00

2026-02-27T17:55:43.000Z - 2 months ago

Generate Biomedicines opens at $15.00, IPO priced at $16.00

Generate Biomedicines opens at $15.00, IPO priced at $16.00

2026-02-27T17:40:41.000Z - 2 months ago

Generate Biomedicines opens at $15.00, IPO priced at $16.00

Drug developer Generate Biomedicines raises $400 million in US IPO

Feb 26, 2026, 8:11 PM EST - 2 months ago

Drug developer Generate Biomedicines raises $400 million in US IPO

Generate Biomedicines 25M share IPO priced at $16.00

2026-02-27T01:05:16.000Z - 2 months ago

Generate Biomedicines 25M share IPO priced at $16.00

Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

Feb 26, 2026, 7:58 PM EST - 2 months ago

Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

Generate Biomedicines aims to raise $425 million in US IPO

Feb 23, 2026, 6:45 AM EST - 2 months ago

Generate Biomedicines aims to raise $425 million in US IPO

Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO

Feb 4, 2026, 5:08 PM EST - 3 months ago

Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO

Generate Biomedicines IPO Registration Document (S-1)

Feb 4, 2026, 5:02 PM EST - 3 months ago

Generate Biomedicines IPO Registration Document (S-1)

Asthma-focused AI biotech Generate Biomedicines files for a $100 million US IPO

Feb 4, 2026, 7:28 AM EST - 3 months ago

Asthma-focused AI biotech Generate Biomedicines files for a $100 million US IPO

MorganHoratio
MorganHoratio May. 16 at 1:01 AM
NVIDIA JUST UPDATED ITS PUBLIC STOCK PORTFOLIO HOLDINGS This is what Nvidia's stock portfolio looked like as of the end of Q1 Generate Biosciences $GENB - 833,325 shares Nokia $NOK - 166,389,351 shares Synopsys $SNPS - 4,821,717 shares Jensen Huang is building an unshakeable empire. Nvidia’s Q1 portfolio proves it's moving way beyond data centers. By holding 4.8M+ shares of $SNPS, Nvidia integrates CUDA into EDA software to control AI chip design at the source. Meanwhile, the massive 166M+ share bet on $NOK (over 8% of its book) is an aggressive play to dominate AI-RAN and turn global cell towers into edge-AI compute nodes. Nokia has quietly transformed from a legacy telecom into an AI infrastructure darling. Which Nvidia-backed proxy has more upside: Synopsys or Nokia? Let's discuss below!
0 · Reply
Johnnytwofour2
Johnnytwofour2 May. 15 at 11:20 PM
$GENB guys, its not the size that matters, its the connection that GENB and NVDA fell that counts. Serious face though, this is a big deal for a company like GENB. Being connected to the largest company in the world opens doors for them that others can only dream of. It might not be a material change this second, but the company is in a better position then they were at the close. They also happen to be trading lower then they were at the close. Seems like simple math to me. Good news + low price = $$$$, can confirm from personal experience that this math checks out sometimes.
0 · Reply
stockexchange01
stockexchange01 May. 15 at 10:35 PM
$GENB Yikes! Need to average down, is it worth it? So little volume.
0 · Reply
samfar
samfar May. 15 at 9:42 PM
$GENB only 117 watchers lol 1000 by Monday $NVDA bought 10M stake.
0 · Reply
Johnnytwofour2
Johnnytwofour2 May. 15 at 9:32 PM
$GENB I'll leave this here for the haters who want to hate, hate, hate, hate, hate. https://www.sec.gov/Archives/edgar/data/1045810/000104581026000042/xslForm13F_X02/information_table.xml
0 · Reply
EnronRetirementPlan
EnronRetirementPlan May. 15 at 9:21 PM
$GENB
0 · Reply
samfar
samfar May. 15 at 9:12 PM
$GENB anyone disputing that $NVDA did not purchase a stake in GENB is an idiot. Read the filing.
0 · Reply
Johnnytwofour2
Johnnytwofour2 May. 15 at 9:11 PM
$GENB This likely rips Monday again, profiteers need their beer money right now. Its been a red day overall in the market so makes sense.
0 · Reply
Olivia_Strickland
Olivia_Strickland May. 15 at 9:05 PM
$GENB down 5.19% AH off a 16 close, which is the polite version of "thanks for the +20% month, now give some back." mcap still 1.9B and the day ran 4.5x avg vol, so somebody got their fill and went home. quiet tape, no catalyst on my screen, just profit-takers tidying up before the weekend. anyone holding this through Monday or are we all flat into the bell? on my morning fade list: https://tapeboard.com/chart/GENB?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=genb-ah-dn-watch
0 · Reply
cloudhedge
cloudhedge May. 15 at 9:01 PM
$NVDA $COHR $CRWV $GENB $INTC NBIS NOK SNPS In its latest SEC Form 13F filing for the new quarter, Nvidia disclosed updated portfolio activity. The company initiated new positions in Coherent, a provider of optical and semiconductor technologies, and Generate Biomedicines, an AI-enabled biotechnology firm. It also increased its stake in cloud infrastructure provider CoreWeave to more than 47 million shares, further strengthening its exposure in the segment. For its existing holdings, Nvidia made no changes to positions in Intel, Nebius Group, Nokia, and Synopsys. Its Intel stake remains above 214 million shares, continuing to serve as a core holding while maintaining its broader exposure across telecommunications and AI hardware ecosystems. Follow me 👉 @cloudhedge for real-time updates and everything. Let’s make moves!
0 · Reply
Bagstand204
Bagstand204 May. 15 at 8:53 PM
$GENB Lol guys read the filings...NVDA didnt take a stake in the company. There are funds that did take a stake dated today, but NVDA is not one of them...go read the filings yourself. Its not true.
2 · Reply
future__investor
future__investor May. 15 at 8:33 PM
$GENB Nvidia stake
0 · Reply
Intradaytrade100
Intradaytrade100 May. 15 at 8:33 PM
$GENB WTF.????????????????......dang.....why did this come down.????????????....I supposed to theink that anything nvidia touches is golden!!!!!!! WTFFFFFF??????????????
0 · Reply
EnronRetirementPlan
EnronRetirementPlan May. 15 at 8:28 PM
$GENB Nvidia take new stake of 833,000 shares
0 · Reply
The_Assassin
The_Assassin May. 15 at 8:24 PM
$GENB $ARAY looks interesting
0 · Reply
AlertsAndNews
AlertsAndNews May. 15 at 8:15 PM
$GENB 13G here. pop on that.
0 · Reply
vu_jade
vu_jade May. 12 at 6:25 PM
$GENB pretty clear above
0 · Reply
staydowngetdown
staydowngetdown May. 5 at 4:24 PM
$GENB
0 · Reply
Washingtonstate
Washingtonstate May. 5 at 4:21 PM
$GENB
0 · Reply
SuperGreenToday
SuperGreenToday May. 4 at 9:05 PM
$GENB
0 · Reply
vu_jade
vu_jade May. 4 at 8:39 PM
$GENB loving this post IPO reversal Could get very interesting
0 · Reply
MiaHarperTrading
MiaHarperTrading Apr. 22 at 11:15 AM
$SPY $LMT $GENB $USO ohhh nooo a terrible accident $BTC.X
0 · Reply